**Supplementary data**

****

**Supplementary figure 1. Ezetimibe and ezetimibe-glucuronide treatments do not affect BUVEC viability.** DMSO,ezetimibe- or ezetimibe-glucuronide-pre-treated BUVEC were treated for 72 h and then incubated 4h with XTT working solution. Bars represent means of three biological replicates ± standard deviation.

**Supplementary table 1.** Representative cycle threshold for NPC1L1 and GAPDH in non- and 6 h p.i. infected BUVEC. Bovine small intestine tissue were used as positive control.

|  |  |  |
| --- | --- | --- |
|  | CT NPC1L1 | CT GAPDH |
| Bovine small intestine | 25,24 | 19,95 |
| 24,79 | 20,01 |
|  |  |
|  |  | CT NPC1L1 | CT GAPDH |  |  | CT NPC1L1 | CT GAPDH |
| BUVEC isolate 1 | n.i. | n.d. | 17,85 | BUVEC isolate 2 | n.i. | 37,87 | 18,34 |
| n.d. | 17,55 | n.d. | 18,19 |
| *T. gondii* 6 h p.i. | n.d. | 19,96 | T. gondii 6 h p.i. | 38,98 | 17,86 |
| 37,35 | 17,45 | 37,63 | 18,22 |
| *N. caninum* 6 h p.i. | n.d. | 18,75 | N. caninum 6 h p.i. | 37,08 | 18,53 |
| n.d. | 19,13 | 37,11 | 18,59 |
| *B. besnoiti* 6 h p.i. | 37,74 | 19,03 | B. besnoiti 6 h p.i. | n.d. | 19,11 |
| 34,94 | 19,03 | n.d. | 19,04 |
|  |  |  |  |  |  |  |  |
|  |  | CT NPC1L1 | CT GAPDH |  |  | CT NPC1L1 | CT GAPDH |
| BUVEC isolate 3 | n.i. | n.d. | 16,18 | BUVEC isolate 4 | n.i. | 37,26 | 16,35 |
| 37,35 | 16,6 | n.d. | 16,26 |
| T. gondii 6 h p.i. | 36,96 | 18,34 | T. gondii 6 h p.i. | 36,19 | 18,41 |
| n.d. | 18,38 | 36,28 | 18,28 |
| N. caninum 6 h p.i. | n.d. | 18,55 | N. caninum 6 h p.i. | n.d. | 19,07 |
| n.d. | 18,58 | 38,24 | 18,59 |
| B. besnoiti 6 h p.i. | 36,91 | 18,57 | B. besnoiti 6 h p.i. | 34,76 | 19 |
| 36,67 | 19,04 | 33,85 | 19,1 |
|  |  | CT NPC1L1 | CT GAPDH |
| BUVEC isolate 5 | n.i. | n.d. | 18,37 |
| n.d. | 18,36 |
| T. gondii 6 h p.i. | n.d. | 18,38 |
| 37,18 | 18,46 |
| N. caninum 6 h p.i. | n.d. | 17,66 |
| n.d. | 17,67 |
| B. besnoiti 6 h p.i. | 33,71 | 18,59 |
| 33,94 | 18,28 |